HC Wainwright Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price

Zymeworks (NYSE:ZYME) had its price target raised by HC Wainwright from $12.00 to $13.00 in a report issued on Monday,Benzinga reports. They currently have a neutral rating on the stock. HC Wainwright also issued estimates for Zymeworks’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a report on Monday, December 16th. Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, March 7th. Finally, Wells Fargo & Company upped their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Trading Up 5.0 %

ZYME stock opened at $12.28 on Monday. Zymeworks has a 1-year low of $7.97 and a 1-year high of $17.70. The firm has a market cap of $854.41 million, a PE ratio of -8.19 and a beta of 1.13. The business’s 50-day moving average price is $14.01 and its two-hundred day moving average price is $13.66.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock in a transaction dated Tuesday, December 24th. The stock was bought at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the purchase, the director now directly owns 14,704,239 shares in the company, valued at approximately $207,623,854.68. This represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jeffrey T. L. Smith sold 11,110 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total value of $165,761.20. Following the completion of the transaction, the executive vice president now owns 8,890 shares of the company’s stock, valued at $132,638.80. The trade was a 55.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 603,539 shares of company stock valued at $8,384,708 and sold 89,601 shares valued at $1,336,847. Company insiders own 1.92% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Polar Asset Management Partners Inc. bought a new position in Zymeworks during the fourth quarter worth about $527,000. Voloridge Investment Management LLC acquired a new position in shares of Zymeworks in the fourth quarter valued at $640,000. Point72 Asset Management L.P. increased its holdings in shares of Zymeworks by 565.8% in the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock valued at $4,833,000 after purchasing an additional 280,544 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of Zymeworks by 0.4% in the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock valued at $3,031,000 after purchasing an additional 886 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock worth $22,645,000 after buying an additional 17,849 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.